1st Quarter - Report

NATIONAL PSORIASIS FOUNDATION for NATIONAL PSORIASIS FOUNDATION

Firm
Client
Income
—
Expenses
$80,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Access to care for people with psoriasis and psoriatic arthritis: H.R.460: Patients' Access to Treatments Act of 2012.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

LobbyistCovered position, as disclosed
NIVA HAYNES —
LEAH MCCORMICK HOWARD —
SARA KOFMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH)

Bills named: H.R. 460 (113th)

Budget/Appropriations BUD

Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC).Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will: Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis; Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and Gain insight into the long-term impact of psoriasis and psoriatic arthritis.

LobbyistCovered position, as disclosed
NIVA HAYNES —
LEAH MCCORMICK HOWARD —
SARA KOFMAN —

Contacted: Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.